Leo Pharma wants to be first in US with hand eczema treatment
After securing fast-track status from the FDA, Leo Pharma hopes to become the first company in the US to specifically address chronic hand eczema, for which there is no treatment in the country.
BY ELIZABETH MØNSTED JOHANSEN, translated by Jonas Sahl Jørgensen
In many ways, Leo Pharma is headed into unknown territory after the firm secured fast-track status for its drug candidate delgocitinib from the US Food and Drug Administration, FDA.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
